肾细胞癌新辅助靶向治疗的不良反应及其防治

肾细胞癌靶向药物主要有索拉菲尼、舒尼替尼、帕唑帕尼、贝伐珠单抗(联合IFN-α)、替西罗莫司、依维莫司及最近批准的阿西替尼,肾癌术前新辅助治疗和术后辅助治疗极大改善了进展期或转移性肾癌患者的预后。与此同时,靶向治疗药物也会引起手足皮肤反应、高血压、乏力、消化道反应等药物相关性不良反应。因此临床中及时发现并采取有效干预措施,对改善患者生活质量和提高靶向治疗效果尤为重要。

Adverse Reactions and Management of Targeted Therapy for Renal Cell Carcinoma

The targeted agents for the treatment of renal cell carcinoma include sorafenib, sunitinib, pazopanib, bevacizumab （in combination with interferon alpha）, temsirolimus, everolimus and recently approved axitinib. As the neoadjuvant therapy in renal cell carcinoma before surgery and adjuvant therapY greatly improved the prognosis of patients with advanced or metastatic renal cell carcinoma . At the same time, the adverse reactions caused by the targeted therapy can result in hand-foot skin reaction （HFSR）,hypertension, fatigue, gastrointestinal reactions, et al. It is very important to manage the adverse events not only to improve the therapeutic efficacy but also to improve the quality of life for patientsl.